160 related articles for article (PubMed ID: 37442659)
21. The pursuit of optimal semaglutide dosing in type 2 diabetes continues.
Sherrill CH; Hwang AY
Lancet; 2023 Aug; 402(10403):668-669. PubMed ID: 37385277
[No Abstract] [Full Text] [Related]
22. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
Edelman SV
J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
[TBL] [Abstract][Full Text] [Related]
23. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
[TBL] [Abstract][Full Text] [Related]
24. Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction.
Hansen MK; Olesen KKW; Gyldenkerne C; Thrane PG; Stødkilde-Jørgensen N; Mortensen MB; Maeng M
J Am Coll Cardiol; 2024 Mar; 83(9):956-958. PubMed ID: 38418010
[No Abstract] [Full Text] [Related]
25. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G; Krauthamer M; Bjalme-Evans M
J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
[TBL] [Abstract][Full Text] [Related]
26. New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation.
Liu Y; Luo X
Front Med; 2022 Feb; 16(1):17-24. PubMed ID: 35226299
[TBL] [Abstract][Full Text] [Related]
27. The evidence for oral semaglutide in type 2 diabetes from a managed care perspective.
Heile M; Taddei-Allen P
Am J Manag Care; 2020 Dec; 26(16 Suppl):S323-S324. PubMed ID: 33439580
[No Abstract] [Full Text] [Related]
28. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.
Newsome P; Francque S; Harrison S; Ratziu V; Van Gaal L; Calanna S; Hansen M; Linder M; Sanyal A
Aliment Pharmacol Ther; 2019 Jul; 50(2):193-203. PubMed ID: 31246368
[TBL] [Abstract][Full Text] [Related]
29. Switching from subcutaneous to oral semaglutide in type 2 diabetes: A prospective study.
Martínez-Montoro JI; Picón-César MJ; Generoso-Piñar M; Fernández-Valero A; López-Montalbán Á; Simón-Frapolli VJ; Hernández-Bayo J; Pinzón-Martín JL; Tinahones FJ
J Intern Med; 2024 Jan; 295(1):113-115. PubMed ID: 37902577
[No Abstract] [Full Text] [Related]
30. Semaglutide reduces the absolute risk of major cardiovascular events by 1.5.
Phizackerley D
BMJ; 2024 Jan; 384():q53. PubMed ID: 38224977
[No Abstract] [Full Text] [Related]
31. Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.
Jendle J; Birkenfeld AL; Polonsky WH; Silver R; Uusinarkaus K; Hansen T; Håkan-Bloch J; Tadayon S; Davies MJ
Diabetes Obes Metab; 2019 Oct; 21(10):2315-2326. PubMed ID: 31215727
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
[TBL] [Abstract][Full Text] [Related]
33. Add-on value of tirzepatide versus semaglutide.
Scheen AJ
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):377-378. PubMed ID: 35468323
[No Abstract] [Full Text] [Related]
34. Semaglutide for Weight Loss: Was It Worth the Weight?: Erratum.
Cardiol Rev; 2023 Jan-Feb 01; 31(1):57. PubMed ID: 36469361
[No Abstract] [Full Text] [Related]
35. Semaglutide in routine clinical practice: interesting news from real-world evidence.
Formoso G; Baroni MG
J Endocrinol Invest; 2022 Aug; 45(8):1599-1600. PubMed ID: 35524036
[No Abstract] [Full Text] [Related]
36. Semaglutide Associated With Less Insulin Need in Early Type 1 Diabetes.
Harris E
JAMA; 2023 Oct; 330(14):1318. PubMed ID: 37728959
[No Abstract] [Full Text] [Related]
37. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Cowart K
Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
[No Abstract] [Full Text] [Related]
38. Reducing cardiovascular outcomes with semaglutide: a metabolic route for a SELECT few.
Liuzzo G; Patrono C
Eur Heart J; 2024 Feb; 45(8):570-571. PubMed ID: 38103177
[No Abstract] [Full Text] [Related]
39. Semaglutide and weight loss - A concern for diabetics and pharmaceuticals.
Admani B; Fahim M; Ahmed H
J Pak Med Assoc; 2024 Jun; 74(6):1204. PubMed ID: 38949006
[No Abstract] [Full Text] [Related]
40. Semaglutide for obesity: four STEPs forward, but more to come.
Ryan DH
Lancet Diabetes Endocrinol; 2021 May; 9(5):252-254. PubMed ID: 33864806
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
